Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. | Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist.
Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...
A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...
This summary highlights significant health news, covering topics such as HIV treatment during U.S. aid pauses, Pfizer's diversity program legal settlement, AstraZeneca's halted UK investment, data ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...
Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback